Children with Down syndrome (DS) have a 40-fold increased risk of acute lymphoblastic leukemia and a 150-fold increased risk of acute myeloid leukemia (AML) before 5 years of age. 1 A modest increase in the risk of leukemia persists into young adulthood.
The age distribution of myeloid leukemia in DS is very distinctive with about 50% of the patients diagnosed at 1 year of age, about one-third at 2 years of age and only 1-2% diagnosed at more than 4 years of age. 2 Myeloid leukemia in younger children with DS has a number of distinctive clinical and laboratory characteristics including a period of thrombocytopenia preceding diagnosis, a predominance of megakaryoblasts, mutations of the hematopoietic transcription factor GATA1 and an excellent outcome when treated on modified AML protocols. [3] [4] [5] [6] These unique features have resulted in this leukemia being recognized as a separate entity in the pediatric classification of myeloid leukemias; myeloid leukemia of Down syndrome (ML-DS). 7 In contrast, less is known about myeloid leukemia in older children with DS, in large part as it is rare. Clinical trial data suggest that older patients may have an inferior survival compared with the generally very favorable outcome in ML-DS. 8, 9 Gamis et al. 8, 9 identified older age as the only independent risk-factor for a poor outcome. However, GATA1 mutations were not analyzed, and it is not clear whether the older patients really were affected with the unique ML-DS or by sporadic AML. Therefore, we studied the clinical features and GATA1 mutation status in DS children with myeloid leukemia aged 4 years or more.
We have identified all DS patients aged 4 years (48 months) and above at time of diagnosis from the databases of the Medical Research Council AML study, Berlin-Frankfurt-Mü nster AML group, European Working Group on childhood Myelodysplastic syndrome, Dutch Childhood Oncology Group and the Nordic Society for Paediatric Haematology Oncology. The accrual period varied from 1972 to 2006. Myeloid leukemia was diagnosed in a total of 317 DS patients of whom only 17 (5%) were 4 years or older. DNA was available from archived bone marrow smears from 10 of the 17 patients (Table 1) . Of the 10 patients, six were boys (Table 2 ) and the median age was 7 years (range, 4-12 years).
Megakaryoblastic leukemia predominates in young children with DS, but was found only in three children in the present study, who all were less than 7 years old. However, the morphologic diagnosis (FAB) of M7 may be difficult and is strongly influenced by the quality of the smears (the marrow is often fibrotic and difficult to aspirate) and the applied markers. The difficulty is reflected in the considerable variation in the frequency of M7, ranging from 65 10 to 100%, 9 in series of DS children with AML. No clinical differences have been demonstrated between young DS patients diagnosed as having M7 or non-M7 myeloid leukemia.
Cytogenetic data were available from all 10 patients; three showed a normal karyotype (with constitutional trisomy 21) and three showed recurrent AML translocations (t(8;21), t(10;11) and t(15;17)). The frequency of recurrent AML aberrations (30%) corresponds to findings in the non-DS population. AML recurrent cytogenetic abnormalities (t(8;21), t(15;17), inv(16) and MLL aberrations) are otherwise very uncommon in DS and have been reported only occasionally in older children or adults with DS. [11] [12] [13] These cases share the common morphologic and cytogenetic features of AML in non-DS individuals. Such cases may represent sporadic AML in an individual with DS. The 7-year-old boy with t(10;11)(p13;q23) had been treated for standard-risk acute lymphoblastic leukemia 4 years earlier. Therapy-related AML has not previously been reported in DS and seems to be less frequent in patients with DS than in those without DS. 2 Genomic DNA was isolated and GATA1 exons 2 and 3 were PCR-amplified. PCR products were directly sequenced and subjected to Direct high Pressure Liquid Chromatography using the WAVE machine (TransgenomicsR, Glasgow, UK).
14 Abnormal WAVE products were sequenced. All PCR products Table 1 Participating study groups with total number of DS patients diagnosed with myeloid leukemia, number of patients aged 4 years or more and number of older patients with available DNA were cloned and sequenced. The sensitivity of the cloning analysis is at the 5% level. GATA1 mutation in the leukemic cells was found in only two children. Since all patients had bone marrow blast counts of more than 20%, low blast count is not a likely explanation for not detecting GATA1 mutations. Both patients with GATA1 mutation were relatively young (4 and 5 years of age), one was diagnosed as AML M0 and one as M7 and both showed a complex karyotype without recurrent AML aberrations. The patient with AML M0 and a GATA1 mutation was the only patient who had been diagnosed with transient myeloproliferative disorder as a newborn. Archived smears from the newborn period showed the same GATA1 mutation as at the time of ML-DS. Both of the two GATA1-mutated patients are in continuous first complete remission. All patients received induction AML chemotherapy and entered complete remission. Four patients (all aged 7 years or more at first diagnosis) experienced a relapse 7-22 months from diagnosis; one of them is alive in second complete remission 5 years from relapse and retreatment with a standard AML regimen. Six patients remain in first complete remission with a median follow-up of 4.9 years. Relapse occurred in four of the six patients without AML-M7 morphology and GATA1 mutation, which is markedly higher than the relapse rate of less than 10% seen in ML-DS. 4, 5 We conclude that myeloid leukemia in older children with DS seems to differ from the characteristic ML-DS and may represent sporadic AML occurring in patients with DS rather than ML-DS in terms of biologic behavior. These patients may require more intensive therapy corresponding to that given in non-DS AML. The restriction of ML-DS to the first years of life is in accordance with the theory of a unique embryonic and fetal progenitor cell as the potential target of the leukemogenic process leading to ML-DS. 15 However, there is no strict age cutoff differentiating ML-DS from sporadic AML in DS. The evaluation of the clinical features, morphology, cytogenetics and specifically the presence of a GATA1 mutation is essential in patients older than 3 years of age. Age is a surrogate marker for ML-DS but GATA1 mutation may be a better marker of the unique ML-DS rather than age, blast count or FAB type. Allogeneic hematopoietic cell transplantation (AHCT) is an efficient and widely used treatment for various hematological diseases. However, the potential benefit of AHCT may be offset by graft-vs-host disease (GvHD) as well as other transplantrelated toxicities. The development of the so-called nonmyeloablative or reduced intensity-conditioning regimens (RICR) has widened the indications of AHCT to a broader spectrum of elderly patients usually not candidate for standard myeloablative AHCT and diseases other than acute leukemia. 1 However, and despite some initial enthusiasm, 1 GvHD remains a matter of concern after RICR AHCT. Moreover, highly immunosuppressive regimens associated with the use of RICR may significantly increase the rate of infectious complications and delay immune reconstitution. 2, 3 Alternative approaches to favor engraftment and limit long-term posttransplant immunosuppression are still needed.
Intravenous (i.v.) apoptotic cell infusion can modulate alloreactivity by interacting with particular dendritic cell subsets. 4 We have previously established that i.v. apoptotic cell infusion facilitates engraftmentFwhen administrated with allogeneic bone marrow (BM) transplantsFwithout triggering autoimmunity or GvHD. 5 This effect relies on a transforming growth factor (TGF)-b-dependent mechanism.
5 Furthermore, i.v. apoptotic cell infusion is associated with a CD4 þ CD25 þ regulatory T cell (Treg) increase early after BM transplantation (BMT; days 6 and 8). 5 These Tregs expressed high levels of Foxp3 transcripts and exerted a potent ex vivo suppressive activity through a cell-to-cell contact mechanism. 5 Nonetheless, such results
5
were achieved without administration of immunosuppressive drugs. In human settings, immunosuppressive treatments are mandatory, at least during the early phase of AHCT, until tolerance is fully established. Since immunosuppressive drugs are capable of interfering with long-term tolerance induction, 6 we investigated whether the widely used immunosuppressive drugs (cyclosporin A, CsA; mycophenolate mofetil, MMF or sirolimus, SRL) can modulate the effect of apoptotic cells coadministered with a hematopoietic graft in a murine BMT model.
BMT was performed, as described, 5 according to institutional guidelines and our local ethic committee. Sublethally irradiated (6 Gy À1 per day from day 0 to 14, diluted in sterilized medium consisting of 160 mg of carboxy-methyl-cellulose (Sigma-Aldrich, Saint Louis, MO, USA) in 80 ml of sterile water, 7 MMF (Roche, Mannheim, Germany) 20 mg kg À1 per day from day 0 to 14, diluted in sterile saline solution. 6 These immunosuppressive regimens were selected as the standard ones used for in vivo immunosuppression in other mouse models. 6, 7 Engraftment was evaluated on peripheral blood cells by flow cytometry analysis (CyAn LX cytometer, DakoCytomation, Fort Collins, CO, USA) at day 30 post-BMT using H-2-or Thy1-specific antibodies (BD Biosciences Pharmingen, Le Pont de Clay, France). 5 Engraftment was considered to be achieved if at least 15% of recipient peripheral leukocytes had the BM donor H-2 q or Thy1.1 phenotype. 5 After confirming the enhancing effect of apoptotic cell infusion on engraftment (40% of engrafted mice vs 5% without apoptotic cell infusion, P ¼ 0.02), we investigated the interactions with the immunosuppressive drugs (Table 1) . CsA treatment did not increase BM engraftment in mice receiving BM alone (14% of engrafted mice in the CsA group vs 5% in the control group, P ¼ 0.76). However, in mice receiving both BM and apoptotic cells, CsA antagonized the favorable effect of apoptotic cells (6% of engrafted mice in the CsA group vs 40% without CsA, P ¼ 0.04). Similarly to CsA, MMF did not significantly promote engraftment in mice receiving BM alone (7% of engrafted mice vs 5% without MMF, P ¼ 0.52). However, and in contrast to CsA, engraftment after BM and apoptotic cells infusion was comparable between MMF-treated and -untreated recipients (40 vs 40% of engrafted mice, P ¼ 0.78). On the other hand, SRL dramatically increased hematopoietic engraftment in the group of mice grafted with BM alone (93% engrafted mice vs 5% without treatment, Po0.0001), as well as in the group grafted with BM and apoptotic cells (100% of engrafted mice vs 40% without treatment; Po0.0001). Engraftment was not significantly different between the group of mice grafted with BM alone (93% of engrafted mice) and those grafted with both BM and apoptotic cells (100% of engrafted mice, P ¼ 0.78) in the presence of SRL (Table 1) .
To decipher a possible synergistic effect of SRL on apoptotic cell-induced engraftment, further experiments were performed with a lower number of BM cells (5 Â 10 5 cells per mouse). Despite this low amount of BM cells, SRL treatment still allowed
